Fate Therapeutics, Inc. (FATE)
| Market Cap | 6.64B |
| Revenue (ttm) | 40.06M |
| Net Income (ttm) | -184.96M |
| Shares Out | 93.43M |
| EPS (ttm) | -2.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $71.51 |
| Previous Close | $72.29 |
| Change ($) | -0.78 |
| Change (%) | -1.08% |
| Day's Open | 73.70 |
| Day's Range | 68.27 - 76.59 |
| Day's Volume | 1,292,040 |
| 52-Week Range | 26.15 - 121.16 |
FATE reports a wider Q1 loss on increased R&D expenses.
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -14.29% and 57.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
IND Application Allowed by FDA for FT538 in Solid Tumors; Clinical Trial to Commence in 2021
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pr...
Two Oral Presentations to Cover iPSC-derived Cell-based Cancer Immunotherapy Pipeline
Here's why she likes them so much.
Here's how shares a diversified e-commerce firm, an immunotherapy biotech, and an electronic agreement company can make you rich.
Eli Casdin on looking for opportunity in life sciences
Eli Casdin, Casdin Capital founder and CIO, on the top life sciences opportunities he sees in the markets, and how he decides which companies are good investments.
The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20% drop in just five trading s...
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for p...
These biotech companies are small, but they have tremendous growth prospects.
Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.
If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covi...
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pr...
FATE reports a wider Q4 loss on increased R&D expenses.
Shares of Fate Therapeutics (NASDAQ:FATE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 64.86% over the past year to ($0.61), which m...
Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...
SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...
The stock price of Fate Therapeutics has seen a solid 16% rise over the last five trading days, while it's up 13% over the last ten trading days, and we believe the rally may continue in the near term. ...
Time will always be on the investor's side.
These two companies are at the forefront of innovation during our golden age of biotech.
After a stellar 5x rise since the March 23 levels of last year, at the current price of around $114 per share we believe Fate Therapeutics stock, a biopharmaceuticals company focused on oncology and imm...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...
SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...
Investors need to pay close attention to Fate Therapeutics (FATE) stock based on the movements in the options market lately.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...
Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.
SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...
Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.
FATE's recent positive pipeline updates have led to a significant upsurge in the stock price.
The biotech's natural killer cell therapies have real potential.
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
Fate Therapeutics (FATE) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Fate (FATE) stock up on positive data from its early-stage study on its NK cell product candidate at ASH.
The stock price of Fate Therapeutics Inc (NASDAQ: FATE) has increased by 37.8% (from $60.79 on December 6 to $83.77 on December 7). This is why.
The biotech reported great news on Friday and Saturday for two of its cancer immunotherapy candidates.
Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2020 Results - Earnings Call Transcript
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -24.14% and -25.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma
SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for c...
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors... [Read more...]
| Industry Biotechnology | IPO Date Oct 1, 2013 |
| CEO William Rastetter | Employees 314 |
| Stock Exchange NASDAQ | Ticker Symbol FATE |
Financial Performance
In 2020, FATE's revenue was $31.43 million, an increase of 194.33% compared to the previous year's $10.68 million. Losses were -$173.39 million, 76.7% more than in 2019.
Analyst Forecasts
According to 16 analysts, the average rating for FATE stock is "Buy." The 12-month stock price forecast is 112.00, which is an increase of 56.62% from the latest price.